Literature DB >> 7536652

Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.

K Iwasaki1, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu, A Fujikawa.   

Abstract

To characterize the metabolic pathway of FK506 (tacrolimus), FK506 or its 31-O-desmethyl metabolite was incubated with liver microsomes prepared from dexamethasone-treated rats in the presence of a NADPH-generating system under aerobic conditions. Besides the four oxidized metabolites already reported, four new metabolites were isolated and identified by HPLC, mass spectrometry, and NMR spectroscopy, and their biological activities were examined. The di-demethylated metabolites at the 15- and 31-, 13- and 31-, and 13- and 15-methoxy groups of FK506, were designated respectively as M-V, M-VI, and M-VII. The fourth, M-VIII, was the metabolite produced after O-demethylation at the 31-methoxy group and formation of a fused 10-membered ring structure through the 19- to 22-carbon of the macrolide ring after oxidation of the 19-methyl group, and of the 36- and 37-vinyl group of FK506. The immunosuppressive activity of the isolated metabolites was estimated in a mouse mixed lymphocyte reaction system and the IC50 values for M-V, M-VI, M-VII, M-VIII, and FK506 were > 1000, 8.78, > 1000, 15.27, and 0.11 ng/ml, respectively. Reactivity of the metabolites with mouse anti-FK506 monoclonal antibody was studied and immunocrossreactivity of M-V was 92.3% of FK506, but no reactivity was observed for M-VI, M-VII, and M-VIII. FK506 thus was metabolized at multiple sites by rat hepatic microsomes and the metabolites formed (M-V) - (M-VIII) exhibited weak or negligible immunosuppressive activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536652

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

Review 1.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

2.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.

Authors:  P Stratta; M Quaglia; T Cena; R Antoniotti; R Fenoglio; A Menegotto; D Ferrante; A Genazzani; S Terrazzino; C Magnani
Journal:  Eur J Clin Pharmacol       Date:  2011-11-20       Impact factor: 2.953

Review 4.  Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients.

Authors:  P E Wallemacq; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  [Heart transplantation--state of the art today].

Authors:  B M Meiser; W von Scheidt; M Weis; D Böhm; F Kur; J Koglin; H Reichenspurner; P Uberfuhr; B Reichart
Journal:  Herz       Date:  1997-10       Impact factor: 1.443

Review 6.  Drug interactions with tacrolimus.

Authors:  Teun van Gelder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 7.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.

Authors:  S Zheng; Y Tasnif; M F Hebert; C L Davis; Y Shitara; J C Calamia; Y S Lin; D D Shen; K E Thummel
Journal:  Clin Pharmacol Ther       Date:  2012-10-17       Impact factor: 6.875

9.  Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats.

Authors:  Hanen Ferjani; Amira El Arem; Aicha Bouraoui; Abedellatif Achour; Salwa Abid; Hassen Bacha; Imen Boussema-Ayed
Journal:  J Physiol Biochem       Date:  2016-01-09       Impact factor: 4.158

Review 10.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.